A
Alexander Martens
Researcher at University of Tübingen
Publications - 27
Citations - 2081
Alexander Martens is an academic researcher from University of Tübingen. The author has contributed to research in topics: Ipilimumab & Antigen. The author has an hindex of 18, co-authored 25 publications receiving 1749 citations. Previous affiliations of Alexander Martens include Newcastle University.
Papers
More filters
Journal ArticleDOI
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.
Benjamin Weide,Alexander Martens,Jessica C. Hassel,Carola Berking,Michael A. Postow,Michael A. Postow,Kees Bisschop,Ester Simeone,J. Mangana,Bastian Schilling,Anna Maria Di Giacomo,Nicole Brenner,Katharina C. Kähler,Lucie Heinzerling,Ralf Gutzmer,Armin Bender,Christoffer Gebhardt,Christoffer Gebhardt,Emanuela Romano,Friedegund Meier,Peter Martus,Michele Maio,Christian U. Blank,Dirk Schadendorf,Reinhard Dummer,Paolo A. Ascierto,Geke A. P. Hospers,Claus Garbe,Jedd D. Wolchok,Jedd D. Wolchok +29 more
TL;DR: High REC and RLC, low LDH, and absence of metastasis other than soft-tissue/lung are independent baseline characteristics associated with favorable OS of patients with melanoma treated with pembrolizumab, indicating a subgroup with excellent prognosis.
Journal ArticleDOI
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.
Alexander Martens,Kilian Wistuba-Hamprecht,Marnix H Geukes Foppen,Jianda Yuan,Michael A. Postow,Phillip Wong,Emanuela Romano,Amir Khammari,Brigitte Dréno,Mariaelena Capone,Paolo A. Ascierto,Anna Maria Di Giacomo,Michele Maio,Bastian Schilling,Antje Sucker,Dirk Schadendorf,Jessica C. Hassel,Thomas Eigentler,Peter Martus,Jedd D. Wolchok,Christian U. Blank,Graham Pawelec,Claus Garbe,Benjamin Weide +23 more
TL;DR: A baseline signature of low LDH, AMC, and MDSCs as well as high AEC, Tregs, and RLC is associated with favorable outcome following ipilimumab.
Journal ArticleDOI
Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A–Specific T Cells
Benjamin Weide,Alexander Martens,Henning Zelba,Christina Stutz,Evelyna Derhovanessian,Anna Maria Di Giacomo,Michele Maio,Antje Sucker,Bastian Schilling,Dirk Schadendorf,Petra Buttner,Claus Garbe,Graham Pawelec +12 more
TL;DR: Circulating MDSC-depleting strategies in the therapeutic setting especially in combination with vaccination or T-cell transfer approaches have a negative impact on survival and inversely correlate with the presence of functional antigen–specific T cells in patients with advanced melanoma.
Journal ArticleDOI
Tumor-necrosis-factor-alpha, interleukin-1-beta, and interleukin-6 plasma-levels in neonatal sepsis
E. S. J. M. de Bont,Alexander Martens,J Van Raan,G Samson,W P F Fetter,Albert Okken,L. H. F. M. de Leij +6 more
TL;DR: Data confirm the abundant presence of TNF α and IL-6 during neonatal sepsis, whereas IL-1 β appeared to be present in small amounts only, and hypothesize that a low IL- 1 β plasma level may explain the lack of a febrile response during Neonatal septicaemia.
Journal ArticleDOI
Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab
Alexander Martens,Kilian Wistuba-Hamprecht,Jianda Yuan,Michael A. Postow,Phillip Wong,Mariaelena Capone,Gabriele Madonna,Amir Khammari,Bastian Schilling,Antje Sucker,Dirk Schadendorf,Peter Martus,Brigitte Dréno,Paolo A. Ascierto,Jedd D. Wolchok,Graham Pawelec,Claus Garbe,Benjamin Weide +17 more
TL;DR: Investigation of changes of peripheral blood biomarkers in advanced melanoma patients found increases in absolute lymphocyte counts observed 2 to 8 weeks after initiation of ipilimumab and delayed increases in CD4+ and CD8+ T cells reflect changes associated with positive outcome.